Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation

被引:56
作者
Mohty, M
Blaise, D
Faucher, C
Vey, N
Bouabdallah, R
Stoppa, AM
Viret, F
Gravis, G
Olive, D
Gaugler, B
机构
[1] Dept Med Oncol, Lab Immunol Tumeurs, Unite Transplantat & Therapie Cellulaire, Marseille, France
[2] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[3] INSERM, UMR 599, F-13258 Marseille, France
[4] Univ Mediterranee, Marseille, France
关键词
D O I
10.1182/blood-2005-07-2919
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study investigated the role of inflammatory cytokines in acute graft-versus-host disease (aGVHD) incidence and severity in 113 patients who underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT). Among all tested cytokines in the first 3 months after allo-SCT, only interleukin-12 p70 (IL-12p70) levels in the first month were significantly associated with grades II to IV aGVHD development (P <.001). IL-12p70 levels were directly correlated with aGVHD severity grade (P <.001). Before aGVHD onset, blood monocytes, the main precursor pool of IL12p70-secreting dendritic cells, recovered more rapidly in patients with grades II to IV aGVHD (P =.005). Similarly, at the effector level, there was a more robust reconstitution of naive CD3(+)CD4(+)CD45RA(+)CD27(+) T cells in patients developing grades II to IV aGVHD (P =.006). In multivariate analysis, IL-12p70 level measured in the first month was the strongest predictive factor for aGVHD development (P <.001). These findings, reconstituting a T(H)1 loop, Support a model in which aGVHD reflects a type I alloreaction after RIC allo-SCT.
引用
收藏
页码:4407 / 4411
页数:5
相关论文
共 27 条
[1]  
COX DR, 1972, J R STAT SOC B, V34, P187
[2]  
Ferrara J L, 1999, Biol Blood Marrow Transplant, V5, P347, DOI 10.1016/S1083-8791(99)70011-X
[3]  
FERRARA JLM, 1993, TRANSPLANT P, V25, P1216
[4]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[5]   GUT INJURY IN MOUSE GRAFT-VERSUS-HOST REACTION - STUDY OF ITS OCCURRENCE AND MECHANISMS [J].
GUYGRAND, D ;
VASSALLI, P .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (05) :1584-1595
[6]   Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation [J].
Holler, E ;
Rogler, G ;
Herfarth, H ;
Brenmoehl, J ;
Wild, PJ ;
Hahn, J ;
Eissner, G ;
Schölmerich, J ;
Andreesen, R .
BLOOD, 2004, 104 (03) :889-894
[7]   MODULATION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) RELEASE IN THE COURSE OF PRETRANSPLANT CONDITIONING - ROLE OF CONDITIONING REGIMENS AND PROPHYLACTIC APPLICATION OF A MONOCLONAL-ANTIBODY NEUTRALIZING HUMAN TNF-ALPHA (MAK 195F) [J].
HOLLER, E ;
KOLB, HJ ;
MITTERMULLER, J ;
KAUL, M ;
LEDDEROSE, G ;
DUELL, T ;
SEEBER, B ;
SCHLEUNING, M ;
HINTERMEIERKNABE, R ;
ERTL, B ;
KEMPENI, J ;
WILMANNS, W .
BLOOD, 1995, 86 (03) :890-899
[8]  
HOLLER E, 1990, BLOOD, V75, P1011
[9]   Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation [J].
Kaiser, T ;
Kamal, H ;
Rank, A ;
Kolb, HJ ;
Holler, E ;
Ganser, A ;
Hertenstein, B ;
Mischak, H ;
Weissinger, EM .
BLOOD, 2004, 104 (02) :340-349
[10]  
Krenger W, 1996, J Hematother, V5, P3, DOI 10.1089/scd.1.1996.5.3